Multiple Sclerosis Fast Facts
In Collaboration With

Original Article Reference
This SciPod is a shortened and simplified summary of ‘Fast Facts: Multiple Sclerosis’ published by Karger Publishers: ISBN 978-1-910797-23-5
The complete original works are available at www.karger.com
Share Episode
Short on time? watch this 3 minute video
About this episode
Multiple sclerosis (MS) is a progressive disease of the nervous system resulting from the inflammation and degeneration of nerves. In developed countries, MS is the primary cause of neurological disability in young and middle-aged people. Worldwide, MS affects an estimated 2.3 million. The cause is unknown and although factors that may increase risk have been identified, attempts to curb disease progression have so far met with failure. However, we are at a turning point in scientific advancement with the emergence of promising new therapies that could help us shift the odds in our favor against this devastating disease.
Related episodes
Addressing antimalarial drug resistance in Africa to ensure patients can continue to be saved
We are pleased to be joined by Dorothy Achu, Regional Malaria Adviser, WHO African Region; Aimable Mbituyumuremyi, Director, National Malaria Control Program, Ministry of Health, Rwanda; Adam Aspinall, Senior Director, Access and Product Management, and George Jagoe, Executive Vice-President Medicines for Malaria Venture. To learn about antimalarial drug resistance in Africa to ensure patients can continue to be saved.
Dr Kerstin Kleinschmidt-Doerr | Could R399E Become a Promising Treatment for Restoring Joints and Relieving Pain in Osteoarthritis?
Osteoarthritis is a painful and progressive joint disorder that affects hundreds of millions of people worldwide. Typically, the options for treating the condition involve exercise or medication to reduce pain. However, these methods do not target the underlying structural problems in the joints of patients. Recently, researchers have uncovered a genetic susceptibility to osteoarthritis associated with a protein called GDF5, which is involved in skeletal growth and development. Alongside a team of scientists across Europe, Dr Kerstin Kleinschmidt-Doerr at Merck has explored a modified form of the GDF5 protein, named R399E, which showed effects in animal models and in-vitro experiments for treating pain and the underlying structural problems in osteoarthritis.
Dr Xiaomu Li | Understanding Diabetes: Revealing the Links Between High Blood Pressure and Insulin Resistance
Cases of type 2 diabetes are on the rise around the world, so gaining a deeper understanding of this chronic condition is vital to ensure early diagnosis and good outcomes for patients. Dr Xiaomu Li and her colleagues at Zhongshan Hospital, Fudan University are conducting important research to understand the risk factors associated with developing type 2 diabetes. Their findings will help healthcare providers to identify patients at high risk of diabetes, enabling early diagnosis and targeted interventions to prevent the development of the condition.
Dr Millie Nakatsuka | Decoding Dizziness in the Emergency Room
Acute vestibular syndrome is one of the most common reasons people present at hospital with dizziness. The symptoms can arise from damage within the brain or the ear, and specialist medical knowledge or equipment is typically needed to determine the specific cause. Dr Nakatsuka from the University of Sydney in Australia has conducted a large-scale analysis and review of the published literature to determine whether well-trained emergency physicians can differentiate between the two causes, using a quick bedside physical examination without expensive special equipment.
This work is licensed under a Creative Commons Attribution 4.0 International License.
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.